Clinical trials
Metastatic Castrate Resistant Prostate Cancer (mCRPC) clinical trials
Below are recruiting metastatic castrate resistant prostate cancer (mcrpc) clinical trials, each written for real people, not researchers. We’re tracking 163 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Duarte, CaliforniaAges 18 years+ - NCT04038502RecruitingPhase 2
Comparing carboplatin and olaparib for prostate cancer with BRCA gene changes
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
West Los Angeles, CaliforniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT03522064RecruitingPhase 2
HRD-positive advanced prostate cancer trial with androgen therapy and chemo
This Phase 2 study tests whether blocking male hormones (androgen therapy) plus the chemotherapy drug carboplatin can shrink advanced prostate cancer in men with specific DNA repair problems. It is for cases where prostate-specific antigen (PSA) is rising even though testosterone is already kept very low.
Sydney, New South WalesAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT07657806RecruitingPhase 1
Study of DEC003M for advanced prostate cancer
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07115446RecruitingPhase 1
Study of HS-20093 and HRS-5041 for advanced prostate cancer
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
ShanghaiAges 18 years+ - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Homewood, AlabamaAges 18–100 - NCT06655259RecruitingPhase 2
TURP with standard therapy for metastatic prostate cancer
This trial tests whether adding a surgery called TURP (transurethral resection of the prostate) to the usual hormone therapy and chemotherapy can help men with metastatic prostate cancer that has spread to lymph nodes, bone, or other organs. The surgery helps relieve urinary symptoms and may improve how well the cancer responds to treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06990880RecruitingPhase 1/Phase 2
A study of a new drug for advanced prostate cancer
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
Phoenix, ArizonaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07319871RecruitingPhase 1
Study of two drugs for prostate cancer
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
Sarasota, FloridaAges 18 years+ - NCT07082920RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
Sarasota, FloridaAges 18 years+ - NCT06663007RecruitingPhase 1/Phase 2
RC48 alone or with envafolimab for advanced prostate cancer with CDK12 changes
This trial tests a drug called RC48, alone or with envafolimab, for men with a specific type of advanced prostate cancer that has not responded to standard treatments. It aims to see if this combination can shrink tumors or slow disease progression.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06334809Recruiting
Genetic test for men with prostate cancer and DNA repair changes
This trial looks for specific DNA repair changes in men with prostate cancer. It tests if these genetic features can help guide treatment decisions. You may join if you have high-risk localized, newly metastatic, or advanced prostate cancer and have tissue available for testing.
Candiolo, TurinAges 18 years+ - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+
Hear when a new Metastatic Castrate Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic castrate resistant prostate cancer (mcrpc)?
- Yes. Clin2 currently lists 163 recruiting metastatic castrate resistant prostate cancer (mcrpc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic castrate resistant prostate cancer (mcrpc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic castrate resistant prostate cancer (mcrpc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Castrate Resistant Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer Metastatic Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.